On Jan. 16, 2025, Colossal Biosciences – the company behind an ambitious, Jurassic Park-style effort to revive extinct bird and mammal species such as the thylacine, dodo and woolly mammoth – said it had raised another $200 million through a Series C funding round led by TWG Global.

The investment values Colossal at $10.2 billion after raising $435 million in total funding. The company said it would use the new capital “to continue to advance its genetic engineering technologies while pioneering new revolutionary software, wetware and hardware solutions, which have applications beyond de-extinction including species preservation and human healthcare.”